Dentons advises Wuhan Easy Diagnosis Biomedicine Co., Ltd. on SZSE SME Board listing

On July 10, 2018, Wuhan Easy Diagnosis Biomedicine Co., Ltd. ("Easy Diagnosis", stock code: 002932) was successfully listed on the small and medium-sized enterprise (SME) Board market of the Shenzhen Stock Exchange. It publicly issued 16,646,287 shares at RMB20.45 per share. The company was advised by a Dentons China team, consisting of senior partner Fang Wang (Wuhan), partner Sherry Li (Beijing), and associates Ping Kang and Yue Li. They provided high-quality and efficient advice on all aspects of the deal, including due diligence, reorganization, standardization, counseling and filing, NEEQ delisting, feedback, and IPO application, successfully resolving a lot of problems for NEEQ-listed companies to get listed on the A-share market.

Established in 2008, Easy Diagnosis is a leading IVD manufacturer, specializing in research & development, production and sales of POCT rapid diagnosis reagents and rapid detection equipment. After years of persistent investment in research and development, Easy Diagnosis has built a comprehensive and efficient POCT quantitative detection platform, and a product mix covering 6 major areas, i.e., infectious disease, cardiovascular disease, kidney disease, obstetrics, gynecology and eugenics, and physical examination, applicable to more than 20 kinds of diseases. The company raised RMB340 million in the IPO and will use the proceeds in IVD production expansion, mobile medical product development, R&D center construction and marketing network establishment, with an aim to further consolidate its leading position in the field of biomedicine.